Background: The outbreak of Coronavirus Disease 2019 (COVID-19) in
December 2019 in China, has become a pandemic in March 2020. COVID-19 is a
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2). This disease with symptoms of fever, cough, and respiratory problems is spread
through droplets and close contact. It started only in China, now COVID-19 has
spread throughout the country. The increase in cases is increasing day by day,
both globally, nationally, and in the city of Semarang. The reuse of existing and
relatively safe drugs is an option. Clinical studies on the use of existing drugs such
as Favipiravir and Oseltamivir are still ongoing worldwide. Methode: This study
aimed to analyze the effectiveness of using Favipiravir and Oseltamivir based on
the difference in the proportion of patients who recovered and those who did not.
The research will be conducted at a COVID-19 referral hospital in Semarang City.
Research Methods: This study is a non-experimental study with a retrospective
approach by tracing the medical record data of confirmed COVID-19 patients who
received Oseltamivir antiviral therapy. The results obtained in the form of the
proportion between cured patients and patients who did not recover with the use
of the antiviral. The proportion of cured and non-cured patients was analyzed using
the Chi-Square test, to see the difference in the proportions. Results: There is a
relationship between the use of oseltamivir therapy with the outcome of confirmed
COVID-19 patients based on the results of the Chi Square test p-value = 0.000
( 60 years. On average, COVID-19
patients were hospitalized for 13.5 days with oseltamivir therapy and 10.26 days
without oseltamivir.
Keyword : COVID-19, proportion, outcome, Oseltamivir, Semarang City